Skip to main content

Table 2 Utility values, utility decrease and costs assigned to health states and adverse drug reactions (ADR)

From: Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

  Utility values Costs in €
Health State Utility Monthly Cost
Healthy 0.86 [17] 0
Remission 0.81 [17] Direct: 35
Indirect: 173
Depressive Episode 0.57 [17] Direct: 190
Indirect: 380
Adverse Drug Reaction Utility Decrease Monthly cost*
Constipation 0.065 [33] 12.5
Diarrhoea 0.044 [33] 5.5
Dyspepsia 0.086 [33] 12.0
Nausea 0.065 [33] 6.0
Somnolence 0.085 [33] 0.0
Headache 0.115 [33] 2.8
Sexual dysfunction 0.049 [33] 44.0
Sleep difficulties 0.08095 [34] 54.0
Discontinuation Symptoms 0.065 [33] 52.0
Study Medication Expected Utility Decrease due to ADR § Monthly medication cost ††
Agomelatine 0.026 60.27
Venlafaxine 0.039 18.03
Escitalopram 0.035 56.31
Fluoxetine 0.026 21.31
Sertraline 0.020 17.35
Generic Venlafaxine   14.38
Generic Escitalopram   45.60
Generic Fluoxetine   14.37
Generic Sertraline   10.81
  1. § Computed based on frequency of ADR and Utility Decrease assigned to each ADR.
  2. Computed based on Experts’ opinion & Government Gazette.
  3. Computed based on Experts’ opinion & Gross Domestic Product from National Statistics Service.
  4. *Computed based on Experts’ opinion and Drug Price Bulletin.
  5. †† Drug Price Bulletin.